Big good news in #Alzhemimers. ~47% early AD on donanemab (29% on placebo) NO clinical progression at 1 year (defined as no decline in CDR-SB). ARIA-E occurred in 24.0% w/ 6.1% experiencing symptomatic ARIA-E, ARIA-H 31.4%. Press release today, below is from previous @NEJM paper. pic.twitter.com/MyCwijf8TO
Teacher, Clinical Supervisor
Clinical Associate Professor, Psychiatry
University of Florida
Affiliation is for identification only. All content and opinions are my own.
View more posts
Gator Psychiatry 